Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma

Danish Medical Journal

Volumn 61, Issue 1, 2014, Pages

  Paulsen, Ida Felbo ^a   Chakera, A H ^b   Drejøe, Jennifer Berg ^a   Klyver, Helle ^a   Dahlstrøm, Karin ^c   Oturai, Peter Sandor ^a   Mortensen, Jann ^a   Hesse, Birger ^a   Schmidt, Grethe ^a   Drzewiecki, Krzysztof ^a  

^a Rigshospitalet   (Denmark)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; COMPARTMENT SYNDROME; DEATH; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; HEMATOMA; HUMAN; HYPERPIGMENTATION; HYPERTHERMIC ISOLATED LIMB PERFUSION; LIMB PAIN; LIMB PERFUSION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; PARESTHESIA; PERIPHERAL EDEMA; SEROMA; SURVIVAL; TOXICITY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION; VERY ELDERLY; WOUND INFECTION; YOUNG ADULT; CLINICAL TRIAL; DISEASE COURSE; HYPERTHERMIC THERAPY; LIMB; LYMPH NODE METASTASIS; METASTASIS; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSPECTIVE STUDY; REGIONAL PERFUSION; SKIN TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; LYMPHATIC METASTASIS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891767008     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Testori A, Verhoef C, Kroon HM et al. Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. J Surg Oncol 2011;104:397-404.
2. Jaques DP, Coit DG, Brennan MF. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1989;169:1-6.
3. Creech O, Jr., Krementz ET, Ryan RF et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-32.
4. Turnbull A, Shah J, Fortner J. Recurrent melanoma of an extremity treated by major amputation. Arch Surg 1973;106:496-8.
5. Deroose JP, Eggermont AM, van Geel AN et al. Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Curr Opin Oncol 2011;23:183-8.
6. de Wilt JH, ten Hagen TL, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000-3.
7. Eggermont AM, van Geel AN, de Wilt JH et al. The role of isolated limb perfusion for melanoma confined to the extremities. Surg Clin North Am 2003;83:371-84, ix.
8. Norda A, Loos U, Sastry M et al. Pharmacokinetics of melphalan in isolated limb perfusion. Cancer Chemother Pharmacol 1999;43:35-42.
9. Minor DR, Allen RE, Alberts D et al. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985;55:2638-44.
10. Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992;16:234-40.
11. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
12. Wieberdink J, Benckhuysen C, Braat RP et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10.
13. World Health Organization. WHO Handbook for reporting results of cancer treatment. Geneva: WHO, 1979.
14. Sanki A, Kroon HM, Kam PC et al. Isolated limb perfusion and isolated limb infusion for malignant lesions of the extremities. Curr Probl Surg 2011;48:371-430.
15. Deroose JP, Eggermont AM, van Geel AN et al. 20 years experience of TNFbased isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol 2012;19:627-35.
16. Deroose JP, Grünhagen DJ, van Geel AN et al. Long-term outcome of isolated limb perfusion with tumour necrosis factor-alpha for patients with melanoma in-transit metastases. Br J Surg 2011;98:1573-80.
17. Noorda EM, van Kreij, Vrouenraets BC et al. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. Eur J Surg Oncol 2007;33:776-82.
18. Knorr C, Melling N, Goehl J et al. Long-term functional outcome after hyperthermic isolated limb perfusion (HILP). Int J Hyperthermia 2008;24:409-14.
19. Riley JL. Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N Engl J Med 2013;369:187-9.